Welcome to our dedicated page for AIM ImmunoTech SEC filings (Ticker: AIMI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on AIM ImmunoTech's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into AIM ImmunoTech's regulatory disclosures and financial reporting.
AIM ImmunoTech reported a first-quarter 2026 net loss of $3.0M on minimal revenues of $22K, reflecting its development-stage status. Operating expenses fell sharply to $2.2M from $3.6M a year earlier, mainly from lower research and general and administrative costs.
Cash and cash equivalents increased to $5.8M at March 31, 2026 from $3.0M at year-end 2025, helped by equity sales, warrant exercises and a $1.8M Series G preferred stock rights offering. Stockholders’ equity improved from a deficit of $(9.8)M to positive equity of $2.1M, aided by an $8.7M reclassification of Class E and F warrants from liability to equity.
The company still faces significant risk: management notes substantial doubt about its ability to continue as a going concern, with working capital constraints, ongoing losses and stockholders’ equity of $2.1M versus the $6M minimum required to maintain NYSE American listing. It relies on additional financings, including Streeterville promissory notes and at-the-market equity sales, while advancing Ampligen for late-stage pancreatic cancer through the DURIPANC Phase 2 study and planning a Phase 3 trial with Thermo Fisher Scientific’s PPD unit.
AIM ImmunoTech Inc. filed a report highlighting a Virtual Investor Key Opinion Leader segment focused on Ampligen (rintatolimod) for late-stage pancreatic cancer. The segment features Professor Casper H.J. van Eijck of Erasmus Medical Center and AIM’s CEO discussing Ampligen’s mechanism, clinical data and development strategy.
The company recaps prior Named Patient Program results suggesting longer progression-free survival and overall survival versus historical controls, and notes ongoing Phase 2 DURIPANC trial work with AstraZeneca’s Imfinzi in metastatic pancreatic cancer. The press release and video segment are furnished, not filed, and include customary forward-looking statement cautions.
AIM ImmunoTech Inc. entered into a warrant exercise inducement agreement with holders of existing warrants covering up to 8,719,928 shares of common stock. Holders agreed to exercise these warrants for cash at a reduced exercise price of $0.48 per share.
In return, the company will issue new Class H Inducement Warrants to purchase up to 17,439,856 shares of common stock at $0.60 per share, with a five-year term starting on the stockholder approval date. If all existing warrants are exercised in full, AIM ImmunoTech expects to receive approximately $4.20 million in gross proceeds for working capital and general corporate purposes.
The company engaged Ladenburg Thalmann as placement agent, agreeing to an 8.0% cash fee on aggregate gross proceeds, a 0.75% management fee, reimbursement of up to $50,000 of expenses, and issuance of placement agent warrants for up to 6% of the exercised shares. The Inducement Warrants were issued under a Section 4(a)(2) exemption and the related shares will be registered for resale after closing.
AIM ImmunoTech Inc. entered into Amendment No. 1 to its Equity Distribution Agreement with Maxim Group LLC, which serves as its exclusive sales agent for an at-the-market stock offering. The original agreement covered issuance and sale of up to $3,000,000 of common shares.
The amendment removes the limitation on the amount of shares that may be sold under the agreement, allowing additional sales under the company’s effective shelf registration statement on Form S-3 and related prospectus. AIM is also filing a new prospectus supplement to increase the number of shares that may be offered and sold through this at-the-market program.
Amid an existing shelf registration, AIM ImmunoTech, Inc. filed a prospectus supplement dated April 10, 2026 to increase the maximum aggregate offering price under its equity distribution agreement with Maxim Group LLC to $3,409,174. The supplement relies on General Instruction I.B.6 of Form S-3 and notes a public float of $10,227,521 calculated using 8,182,017 shares held by non‑affiliates at $1.25 per share (closing price on February 13, 2026).
The company states it has sold $2,288,758.60 under the instruction during the prior 12 months and is eligible to sell an additional $1,120,415. Sales, if any, may be made as “at the market offerings” through Maxim, which may receive compensation up to 3.0% of gross proceeds. The supplement affirms Maxim will be deemed an underwriter for these sales and that indemnification provisions apply.
AIM ImmunoTech Inc. reports on an extensive R&D pipeline centered on its dsRNA drug Ampligen for late-stage pancreatic cancer, other solid tumors, antivirals, ME/CFS and post-COVID conditions, plus legacy product Alferon N Injection. The company highlights promising early- and mid-stage clinical data, orphan drug designations and multiple patents supporting oncology and antiviral strategies.
At the same time, AIM discloses recurring operating losses, net cash use, a working capital deficit and a stockholders’ deficit of approximately $9,783,000 as of December 31, 2025, leading management to conclude that substantial doubt exists about its ability to continue as a going concern. AIM is also not in compliance with NYSE American stockholders’ equity requirements and faces a potential delisting if it cannot raise equity above $6,000,000 by June 11, 2026, despite having regained compliance with minimum price rules via a 1‑for‑100 reverse split in 2025.
Mitigating steps include a third‑quarter 2025 vendor settlement that forgave $3,041,000 of legal fees in exchange for $1,875,000 of payments, recorded as other income, and a January 2026 stock dividend that reset Class E and F warrant terms, reduced their exercise price to $1.439 and allowed those warrants to be reclassified from liabilities to equity, which AIM states will significantly increase stockholders’ equity. The company also signed an agreement with Thermo Fisher Scientific’s PPD clinical research business to design an anticipated Phase 3 trial of Ampligen in late‑stage pancreatic cancer, reflecting its strategic focus on this indication as its most attractive commercial opportunity.
AIM ImmunoTech Inc. CEO and President Thomas K. Equels converted 25 shares of Series G Convertible Preferred Stock into 25,000 shares of common stock. The preferred stock position was reduced to zero, and his directly held common stock increased to 63,922 shares following the transaction.
AIM ImmunoTech Inc. director David I. Chemerow converted preferred stock into common shares. He converted 25 shares of Series G Convertible Preferred Stock into 25,000 shares of common stock through a derivative conversion at no stated cash price. A footnote explains each preferred share is convertible into 1,000 common shares, effectively valuing the conversion at $1.00 per common share. Following the conversion, he directly holds 28,441 shares of AIM ImmunoTech common stock, with no remaining Series G preferred shares reported.
AIM ImmunoTech director David I. Chemerow reported new derivative holdings tied to a rights offering. He now holds 25 shares of Series G Convertible Preferred Stock, each with a stated value of $1,000 and convertible into 1,000 shares of common stock, issued through a subscription right in a rights offering.
He also reported 50,000 Class G Warrants, each exercisable for one share of common stock at an exercise price of $1.00, likewise issued as part of a subscription right in a rights offering. Following these transactions, he directly holds 3,441 shares of common stock, alongside the preferred shares and warrants.
AIM ImmunoTech Inc. completed a previously announced rights offering, raising approximately $1.8 million by selling 1,842 units. Each unit included one share of Series G Convertible Preferred Stock and Class G warrants.
The company created a new Series G preferred series of 12,000 shares, each with a stated value of $1,000 and initially convertible into common stock at $1.00 per share, subject to standard anti-dilution adjustments. Conversions are limited so that holders generally cannot exceed 4.99% beneficial ownership, adjustable by the holder up to 9.99%. The rights offering also issued 3,684,000 Class G warrants, each exercisable for one share of common stock at $1.00 per share for five years. The Series G preferred is non-voting (with limited exceptions), participates with common stock in dividends and liquidation on an as-converted basis, and has no mandatory redemption features.